Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of chirwere chetachiona.
Eisai akati Lenvima ichave chiyero chitsva chekurapa kwegomarara regomarara risingagadzirike. Indasitiri iyi inotarisira zvikuru pamusoro peLenvima, uye zvinotarisirwa kuti mushonga wacho uchave mombe itsva yemari yeEisai, nekutengesa kwegore negore kunowedzera kudarika $ 1 bhiriyoni.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tumarara volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Parizvino, kunyange zvazvo mhando dzakawanda dzegomarara rethyroid richikwanisa kurapwa, pane zvishoma zvingasarudzwa zvekurapwa kana zvanyanya kuipa. Differential thyroid cancer (DTC) ndiyo inonyanya kuipa yegomarara rethyroid, uye chiitiko chayo chakawedzera zvishoma mumakore achangopfuura.
Lenvatinib inonzi oral multi-receptor tyrosine kinase (RTK) inhibitor ine novel binding mode. Pamusoro pekudzivisa mamwe maRTK anobatanidzwa mukuwedzera kwebundu uye oncogenic masaini nzira, inogona zvakare kusarudza kurambidza vascular endothelial growth factor (VEGF) receptor kinase chiitiko.
